Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: A 12-month open trial

International Journal of Neuropsychopharmacology

Volumn 8, Issue 3, 2005, Pages 427-438

  Lasser, Robert A ^a   Bossie, Cynthia A ^a   Gharabawi, Georges M ^a   Baldessarini, Ross J ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Injectable long acting risperidone; Oral risperidone; Schizoaffective disorder; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PROPRANOLOL; RISPERIDONE;

ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BRADYKINESIA; CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; OPEN STUDY; PARANOID SCHIZOPHRENIA; PARKINSONISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 22344437632     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005225     Document Type: Article

References (42)

1. Adams CE, Fenton MK, Quraishi S, David AS (2001). Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 279, 290-299.
2. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E (2003). Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs 63, 493-512.
3. Baldessarini RJ (1994). Enhancing treatment with psychotropic medicines. Bulletin of the Menninger Clinic 58, 224-241.
4. Baldessarini RJ, Tarazi FI (2001). Drugs and the treatment of psychiatric disorders: Antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics (10th edn) (pp. 485-520). New York: McGraw-Hill Press.
5. Barnes TR, Curson DA (1994). Long-term depot antipsychotics: risk-benefit assessment. Drug Safety 10, 464-479.
6. Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980). The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurology 7, 233.
7. Cramer JA, Rosenheck R (1998). Compliance with medication regimens for mental and physical disorders. Psychiatric Services 49, 196-201.
8. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60, 533-564.
9. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L (1994). Depot antipsychotic drugs: place in therapy. Drugs 47, 741-773.
10. DeQuardo JR, Tandon R (1998). Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? Journal of Psychiatric Research 32, 229-242.
11. Desai NM, Hug Z, Martin SD, McDonald G (1999). Switching from depot antipsychotics to risperidone: Results of a study in chronic schizophrenia. Advances in Therapy 16, 78-88.
12. Docherty JP, Grogg AL, Kozma C, Lasser R (2003). Antipsychotic partial compliance: impact on clinical outcomes in schizophrenia. American Psychiatric Association 2003 Annual Meeting, San Francisco, 17-22 May 2003. New Research Abstracts; NR172: 63.
13. Dolder CR, Lacro JP, Dünn LB, Jeste DV (2002). Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry 159, 103-108.
14. Eerdekens M, Hove IV, Remmerie B, Mannaert E (2004). Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Research 70, 91-100.
15. Fenton WS, Blyler CR, Heinssen RK (1997). Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 23, 637-651.
16. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P-M, Chrzanowski W, Martin S, Gefvert O (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month, open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry 64, 1250-1257.
17. Guy W (1976). Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology Revised (pp. 217-222). Rockville, MD: US DHEW.
18. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 36, 1283-1294.
19. Kane JM, Aguglia E, Altamura AC, Ayuso-Guttierez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindstrom E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 8, 55-66.
20. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 160, 1125-1132.
21. Kay SR, Fiszbein A, Opler L (1987). The Positive and Negative Syndrome Scale for schizophrenia (PANSS). Schizophrenia Bulletin 13, 261-276.
22. Labelle A, Bourget D, Boulay LJ, Ellis J, Tessier P (2002). Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. Journal of Clinical Psychopharmacology 22, 545-553.
23. Lasser RA, Bossie CA, Gharabawi GM, Turner M (2004). Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. European Psychiatry 19, 219-225.
24. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003). Relapse prevention in schizophrenia with new-generation antipsychotics: Systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry 160, 1209-1222.
25. Littlejohn R, Leslie F, Cookson J (1994). Depot antipsychotics in the prophylaxis of bipolar affective disorder. British Journal of Psychiatry 165, 827-829.
26. Littrell KH (1999). Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open-label randomized trial. American Psychiatric Association 1999 Annual Meeting, Washington, DC, 15-20 May 1999. New Research Program & Abstracts; NR555: 223.
27. Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D (2004). Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder. Clinical Drug Investigation 24, 275-286.
28. Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry 58, 538-546.
29. Marriott P, Hiep A (1976). A mirror-image outpatient study at a depot phenothiazine clinic. Australian and New Zealand Journal of Psychiatry 10, 163-167.
30. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR (1998). Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. American Journal of Health-System Pharmacy 55 (Suppl. 4), S17-S19.
31. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ (2000). Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatric Services 51, 216-222.
32. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA (2002). Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research 57, 209-219.
33. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D (2000). Medication continuation and compliance: comparison of patients treated with clozapine and haloperidol. Journal of Clinical Psychiatry 61, 382-386.
34. Svarstad BL, Shireman TI, Sweeney JK (2001). Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services 52, 805-811.
35. Schultz SK, Andreasen NC (1999). Schizophrenia. Lancet 353, 1425-1430.
36. Swartz MS, Swanson JW, Wagner HR, Burns BJ, Hiday VA (2001). Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. Journal of Nervous and Mental Disease 189, 583-592.
37. Turner M, Eerdekens E, Jacko M, Eerdekens M (2004). Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. International Clinical Psychopharmacology 19, 241-249.
38. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T (2002). Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40, 630-639.
39. van Os J, Bossie CA, Lasser RA (2004). Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotic therapy to long-acting risperidone. International Clinical Psychopharmacology 19, 229-232.
40. Weiden P, Kozma C, Grogg A, Locklear J (2004). Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services 55, 886-891.
41. White E, Cheung P, Silverstone T (1993). Depot antipsychotics in bipolar affective disorder. International Clinical Psychopharmacology 8, 119-122.
42. Young JL, Zonana HV, Shepler L (1986). Medication noncompliance in schizophrenia: codification and update. Bulletin of the American Academy of Psychiatry and the Law 14, 105-122.